BioMarin Pharmaceutical Inc. - Common Stock (BMRN) stock analysis
BMRN · BioMarin Pharmaceutical Inc. - Common Stock
Latest recorded price: USD 57.99
Model-estimated fair value: USD 6.40. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $57.99, BMRN trades 806.2% above the model's base-case value of $6.40. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $0.32 in the conservative case and $13.79 in the optimistic case, with a valuation confidence score of 55/100. About 74% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 15.4%, free cash flow margin 22.5%, ROIC 3.4%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Celldex Therapeutics, Inc. (CLDX)
- Corcept Therapeutics Incorporated - Common Stock (CORT)
- CRISPR Therapeutics AG - Common Shares (CRSP)
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)